Goal 2: Reduce Human Disease

Transplant to Cure Older Adults with Hematologic Malignancy-Removing the Blindfold

While transplant for patients 60 and older for high-risk hematologic malignancies has increased and observational data are promising, the risks and benefits of translant versus non-transplant remain largely unknown. We now have the tools and mechanisms to remove the blindfold!


The NHLBI should support the cooperative groups in conjunction with the BMT-CTN to establish a common framework for transplant trials in older patients, especially for AML, MDS and ALL.This can be done by randomization, donor/no donor, or comparative effectiveness and must include core measures of health (comorbidity, function), baseline disease measures and patient centered outcomes. The framework can apply across studies of typical diseases.

Tags (Keywords associated with the idea)


20 net votes
36 up votes
16 down votes
Idea No. 685